Charles Schwab’s Lexeo Therapeutics LXEO Stock Holding History

Charles Schwab’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$803K	Sell	172,609 -9,460	-5%	-$51.2K	﹤0.01%	3072
2026 Q1	$1.05M	Sell	182,069 -10,141	-5%	-$71.9K	﹤0.01%	2896
2025 Q4	$1.91M	Buy	192,210 +86,450	+82%	+$789K	﹤0.01%	2768
2025 Q3	$702K	Buy	105,760 +41,540	+65%	+$201K	﹤0.01%	3066
2025 Q2	$258K	Buy	64,220 +8,046	+14%	+$26.5K	﹤0.01%	3347
2025 Q1	$195K	Sell	56,174 -7,700	-12%	-$34.1K	﹤0.01%	3262
2024 Q4	$420K	Hold	63,874	–	–	﹤0.01%	3189
2024 Q3	$577K	Buy	63,874 +33,013	+107%	+$394K	﹤0.01%	3114
2024 Q2	$495K	Buy	30,861 +3,500	+13%	+$50.8K	﹤0.01%	3198
2024 Q1	$429K	Buy	+27,361	New	+$428K	﹤0.01%	3081

Other funds holding LXEO

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Jupiter Topco New York $245B AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Charles Schwab's LXEO Position: Q2 2026 in Review

Charles Schwab reduced its Lexeo Therapeutics (LXEO) stake by 5.2% in Q2 2026, selling an estimated $51.2K and leaving 172,609 shares worth $803K. The position accounts for ﹤0.01% of the portfolio, ranked #3072.

Charles Schwab first reported a position in LXEO in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.91M in Q4 2025. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

Charles Schwab held 172,609 shares of Lexeo Therapeutics worth $803K as of Q2 2026.
Charles Schwab sold 9,460 Lexeo Therapeutics shares in Q2 2026, an estimated $51.2K.
Lexeo Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3072 holding.
Charles Schwab first reported a position in Lexeo Therapeutics in Q1 2024 and has held it in 10 quarters since.
Charles Schwab's Lexeo Therapeutics position peaked at $1.91M in Q4 2025.
142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.